Biomea Fusion Announces Positive 52-Week Results from Phase 2 COVALENT-112 Trial in Type 1 Diabetes Showing C-Peptide Improvement and Durability Following 12-Weeks of Icovamenib Treatment
Go back to Biomea Fusion Announces Positive 52-Week Results from Phase 2 COVALENT-112 Trial in Type 1 Diabetes Showing C-Peptide Improvement and Durability Following 12-Weeks of Icovamenib Treatment| (NASDAQ: BMEA) | Delayed: 1.23 +0.05 (4.24%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $1.18 | 52 Week High | $ | |||
| Open | $1.18 | 52 Week Low | $ | |||
| Day High | $1.28 | P/E | N/A | |||
| Day Low | $1.18 | EPS | $ | |||
| Volume | 1,067,715 | |||||
